nach oben

Drugs & Aging

Erschienen in:

06.05.2016 | Review Article

Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance

verfasst von: Alla Ishchenko, Rik J. Lories

Erschienen in: Drugs & Aging | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

The population of older individuals with rheumatoid arthritis (RA) is rapidly expanding, mainly due to increased life expectancy. While targeted biological therapies are well established for the treatment of this disease, their use may be lower in older patients (age > 65 years) and very old patients (age > 75 years) as a result of perceived higher risks for adverse events in this population, taking into account comorbidity, polypharmacy, and frailty. In this review, we discuss the available evidence for the use of biological therapies in this growing patient group with specific attention towards the eventual reasons for biological treatment failure or withdrawal. The majority of data is found in secondary analyses of clinical trials and in retrospective cohorts. The most information available is on tumor necrosis factor (TNF) blockers. Older patients seem to have a less robust response to anti-TNF agents than a younger population, but drug survival as a proxy for efficacy does not seem to be influenced by age. Despite an overall rate of adverse effects comparable to that in younger patients, older RA patients are at higher risk of serious infections. Other biologics appear to have an efficacy similar to anti-TNF agents, also in older RA patients. Again, the drug survival rates for tocilizumab, rituximab, and abatacept resemble those in young RA patients with good general tolerability and safety profiles. The cardiovascular risk and the risk of cancer, increased in RA patients and in the older RA patients, do not appear to be strongly influenced by biologicals.

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19. doi:10.1056/NEJMra1004965.PubMedCrossRef

Rudan I, Sidhu S, Papana A, Meng SJ, Xin-Wei Y, Wang W, et al. Prevalence of rheumatoid arthritis in low- and middle-income countries: a systematic review and analysis. J Glob Health. 2015;5(1):010409. doi:10.7189/jogh.05.010409.PubMedCrossRef

Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Modern Rheumatol Jpn Rheum Assoc. 2014;24(1):33–40. doi:10.3109/14397595.2013.854059.CrossRef

Brighton SW, de la Harpe AL, van Staden DJ, Badenhorst JH, Myers OL. The prevalence of rheumatoid arthritis in a rural African population. J Rheumatol. 1988;15(3):405–8.PubMed

Dowman B, Campbell RM, Zgaga L, Adeloye D, Chan KY. Estimating the burden of rheumatoid arthritis in Africa: a systematic analysis. J Glob Health. 2012;2(2):020406. doi:10.7189/jogh.02.020406.PubMedPubMedCentralCrossRef

Carbonell J, Cobo T, Balsa A, Descalzo MA, Carmona L, Group SS. The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology (Oxford). 2008;47(7):1088–92. doi:10.1093/rheumatology/ken205.CrossRef

Soubrier M, Mathieu S, Payet S, Dubost JJ, Ristori JM. Elderly-onset rheumatoid arthritis. Joint Bone Spine. 2010;77(4):290–6. doi:10.1016/j.jbspin.2010.04.004.PubMedCrossRef

Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum. 2003;48(4):917–26. doi:10.1002/art.10897.PubMedCrossRef

Ranganath VK, Furst DE. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin North Am. 2007;33(1):197–217. doi:10.1016/j.rdc.2006.12.011.PubMedCrossRef

10.

Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(7):990–7. doi:10.1002/acr.22281.PubMedCrossRef

11.

Boots AM, Maier AB, Stinissen P, Masson P, Lories RJ, De Keyser F. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(10):604–13. doi:10.1038/nrrheum.2013.92.PubMedCrossRef

12.

Lang PO, Michel JP, Zekry D. Frailty syndrome: a transitional state in a dynamic process. Gerontology. 2009;55(5):539–49. doi:10.1159/000211949.PubMedCrossRef

13.

Lindstrom TM, Robinson WH. Rheumatoid arthritis: a role for immunosenescence? J Am Geriatr Soc. 2010;58(8):1565–75. doi:10.1111/j.1532-5415.2010.02965.x.PubMedPubMedCentralCrossRef

14.

Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128(1):92–105. doi:10.1016/j.mad.2006.11.016.PubMedCrossRef

15.

van der Geest KS, Abdulahad WH, Tete SM, Lorencetti PG, Horst G, Bos NA, et al. Aging disturbs the balance between effector and regulatory CD4+ T cells. Exp Gerontol. 2014;60:190–6. doi:10.1016/j.exger.2014.11.005.PubMedCrossRef

16.

Vallejo AN, Mueller RG, Hamel DL Jr, Way A, Dvergsten JA, Griffin P, et al. Expansions of NK-like alphabetaT cells with chronologic aging: novel lymphocyte effectors that compensate for functional deficits of conventional NK cells and T cells. Ageing Res Rev. 2011;10(3):354–61. doi:10.1016/j.arr.2010.09.006.PubMedPubMedCentralCrossRef

17.

Vallejo AN, Schirmer M, Weyand CM, Goronzy JJ. Clonality and longevity of CD4+ CD28 null T cells are associated with defects in apoptotic pathways. J Immunol. 2000;165(11):6301–7.PubMedCrossRef

18.

de Vlam K, De Keyser F, Verbruggen G, Vandenbossche M, Vanneuville B, D’Haese D, et al. Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol. 1993;11(4):393–7.PubMed

19.

Lin Y, Damjanovic A, Metter EJ, Nguyen H, Truong T, Najarro K, et al. Age-associated telomere attrition of lymphocytes in vivo is co-ordinated with changes in telomerase activity, composition of lymphocyte subsets and health conditions. Clin Sci (Lond). 2015;128(6):367–77. doi:10.1042/CS20140481.PubMedCrossRef

20.

Chen YM, Chen LK, Lan JL, Chen DY. Geriatric syndromes in elderly patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(10):1261–4. doi:10.1093/rheumatology/kep195.CrossRef

21.

Mikuls T, Saag K, Criswell L, Merlino L, Cerhan JR. Health related quality of life in women with elderly onset rheumatoid arthritis. J Rheumatol. 2003;30(5):952–7.PubMed

22.

Huscher D, Sengler C, Gromnica-Ihle E, Bischoff S, Eidner T, Ochs W, et al. Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account. Clin Exp Rheumatol. 2013;31(2):256–62.PubMed

23.

Ranganath VK, Maranian P, Elashoff DA, Woodworth T, Khanna D, Hahn T, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford). 2013;52(10):1809–17. doi:10.1093/rheumatology/ket224.CrossRef

24.

Cho SK, Sung YK, Choi CB, Cha HS, Choe JY, Chung WT, et al. Do patients with elderly-onset rheumatoid arthritis have severe functional disability? Semin Arthritis Rheum. 2012;42(1):23–31. doi:10.1016/j.semarthrit.2012.02.004.PubMedCrossRef

25.

Abdel-Nasser AM, Abd El-Azim S, Taal E, El-Badawy SA, Rasker JJ, Valkenburg HA. Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. Br J Rheumatol. 1998;37(4):391–7.PubMedCrossRef

26.

van der Heijde DM, van Riel PL, van Leeuwen MA, van’t Hof MA, van Rijswijk MH, van de Putte LB. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol. 1991;18(9):1285–9.PubMed

27.

Arnold MB, Bykerk VP, Boire G, Haraoui BP, Hitchon C, Thorne C, et al. Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. Rheumatology (Oxford). 2014;53(6):1075–86. doi:10.1093/rheumatology/ket449.CrossRef

28.

Koller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology (Oxford). 2009;48(12):1575–80. doi:10.1093/rheumatology/kep291.CrossRef

29.

Sugihara T, Ishizaki T, Hosoya T, Iga S, Yokoyama W, Hirano F, et al. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE). Rheumatology (Oxford). 2015;54(5):798–807. doi:10.1093/rheumatology/keu395.CrossRef

30.

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65(3):353–61. doi:10.1002/acr.21812.PubMedCrossRef

31.

Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006;65(12):1608–12. doi:10.1136/ard.2005.050377.PubMedPubMedCentralCrossRef

32.

England BR, Sayles H, Michaud K, Caplan L, Davis LA, Cannon GW, et al. Cause-specific mortality in US veteran men with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015;. doi:10.1002/acr.22642.PubMed

33.

Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212. doi:10.1186/s13075-015-0728-9.PubMedPubMedCentralCrossRef

34.

Hemminki K, Li X, Sundquist K, Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology (Oxford). 2008;47(5):698–701. doi:10.1093/rheumatology/ken130.CrossRef

35.

Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, Ranganathan P. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford). 2011;50(8):1431–9. doi:10.1093/rheumatology/ker113.CrossRef

36.

Khurana R, Wolf R, Berney S, Caldito G, Hayat S, Berney SM. Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol. 2008;35(9):1704–8.PubMed

37.

Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65(9):1226–9. doi:10.1136/ard.2005.051144.PubMedPubMedCentralCrossRef

38.

Jin XM, Lee J, Choi NK, Seong JM, Shin JY, Kim YJ, et al. Utilization patterns of disease-modifying antirheumatic drugs in elderly rheumatoid arthritis patients. J Korean Med Sci. 2014;29(2):210–6. doi:10.3346/jkms.2014.29.2.210.PubMedPubMedCentralCrossRef

39.

Harrison MJ, Kim CA, Silverberg M, Paget SA. Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis? J Rheumatol. 2005;32(7):1243–8.PubMed

40.

Iwanaga N, Arima K, Terada K, Ueki Y, Horai Y, Suzuki T, et al. Risk factors of adverse events during treatment in elderly patients with rheumatoid arthritis: an observational study. Int J Rheum Dis. 2014;. doi:10.1111/1756-185X.12348.

41.

Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, et al. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2015;67(5):624–32. doi:10.1002/acr.22510.PubMedPubMedCentralCrossRef

42.

Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C, et al. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007;57(4):679–85. doi:10.1002/art.22688.PubMedCrossRef

43.

Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–32. doi:10.1002/art.27227.PubMedCrossRef

44.

Radovits BJ, Fransen J, Eijsbouts A, van Riel PL, Laan RF. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(8):906–10. doi:10.1093/rheumatology/kep129.CrossRef

45.

Ng B, Chu A, Khan MM. A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers. BMJ Open. 2013. doi:10.1136/bmjopen-2012-002468.

46.

Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006;33(2):234–43.PubMed

47.

Fleischmann RM, Baumgartner SW, Tindall EA, Weaver AL, Moreland LW, Schiff MH, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol. 2003;30(4):691–6.PubMed

48.

Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging. 2006;23(2):167–78.PubMedCrossRef

49.

Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics R. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45(12):1558–65. doi:10.1093/rheumatology/kel149.CrossRef

50.

Radovits BJ, Kievit W, Fransen J, van de Laar MA, Jansen TL, van Riel PL, et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68(9):1470–3. doi:10.1136/ard.2008.094730.PubMedCrossRef

51.

Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol. 2010;38(2–3):90–6. doi:10.1007/s12016-009-8142-1.PubMedCrossRef

52.

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253–9. doi:10.1056/NEJM199901283400401.PubMedCrossRef

53.

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Int Med. 1999;130(6):478–86.PubMedCrossRef

54.

Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586–93. doi:10.1056/NEJM200011303432201.PubMedCrossRef

55.

Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675–81. doi:10.1016/S0140-6736(04)15640-7.PubMedCrossRef

56.

Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging. 2007;24(3):239–54.PubMedCrossRef

57.

Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(3):373–82. doi:10.1002/acr.20372.PubMed

58.

Bryl E, Vallejo AN, Matteson EL, Witkowski JM, Weyand CM, Goronzy JJ. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum. 2005;52(10):2996–3003. doi:10.1002/art.21353.PubMedCrossRef

59.

Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016;55(3):523–34. doi:10.1093/rheumatology/kev374.

60.

Majithia V, Peel C, Geraci SA. Rheumatoid arthritis in elderly patients. Geriatrics. 2009;64(9):22–8.PubMed

61.

Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65(3):379–84. doi:10.1136/ard.2005.035287.PubMedPubMedCentralCrossRef

62.

Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124–31. doi:10.1093/rheumatology/keq242.CrossRef

63.

Toh S, Li L, Harrold LR, Bayliss EA, Curtis JR, Liu L, et al. Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics? Pharmacoepidemiol Drug Saf. 2012;21(5):524–34. doi:10.1002/pds.3238.PubMedPubMedCentralCrossRef

64.

Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(6):1754–64. doi:10.1002/art.22600.PubMedCrossRef

65.

Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, et al. TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine. 2011;90(2):139–45. doi:10.1097/MD.0b013e318211106a.PubMedPubMedCentralCrossRef

66.

McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48(10):1364–71. doi:10.1086/598331.PubMedPubMedCentralCrossRef

67.

Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med. 2005;352(22):2266–7. doi:10.1056/NEJMp058091.PubMedCrossRef

68.

Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, et al. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis. 2015;74(6):1065–71. doi:10.1136/annrheumdis-2013-204011.PubMedCrossRef

69.

Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53(10):1872–85. doi:10.1093/rheumatology/keu172.CrossRef

70.

Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-alpha) targeted biologics and recently licensed TNF-alpha inhibitors: data from clinical trials and national registries. J Rheumatol Suppl. 2014;91:56–64. doi:10.3899/jrheum.140103.PubMedCrossRef

71.

Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, Graham DJ, et al. Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum. 2013;65(1):48–58. doi:10.1002/art.37740.PubMedCrossRef

72.

Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;. doi:10.1136/annrheumdis-2015-207870.

73.

Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008;156(2):336–41. doi:10.1016/j.ahj.2008.02.025.PubMedPubMedCentralCrossRef

74.

Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst DE. Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open. 2015;1(1):e000080. doi:10.1136/rmdopen-2015-000080.PubMedPubMedCentralCrossRef

75.

Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, et al. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis. 2013;72(11):1813–8. doi:10.1136/annrheumdis-2012-202136.PubMedCrossRef

76.

Schau T, Gottwald M, Arbach O, Seifert M, Schopp M, Neuss M, et al. Increased prevalence of diastolic heart failure in patients with rheumatoid arthritis correlates with active disease, but not with treatment type. J Rheumatol. 2015;42(11):2029–37. doi:10.3899/jrheum.141647.PubMedCrossRef

77.

Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Modern Rheumatol Japan Rheum Assoc. 2009;19(1):12–9. doi:10.1007/s10165-008-0125-1.CrossRef

78.

Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817–29. doi:10.1002/art.22033.PubMedCrossRef

79.

Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int. 2011;31(11):1493–9. doi:10.1007/s00296-010-1526-y.PubMedCrossRef

80.

Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2010;37(2):234–45. doi:10.3899/jrheum.091066.PubMedCrossRef

81.

Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Modern Rheumatol Japan Rheum Assoc. 2011;21(2):122–33. doi:10.1007/s10165-010-0366-7.CrossRef

82.

Sugihara T, Harigai M. Targeting low disease activity in elderly-onset rheumatoid arthritis: current and future roles of biological disease-modifying antirheumatic drugs. Drugs Aging. 2016;33(2):97–107. doi:10.1007/s40266-015-0341-2.PubMedPubMedCentralCrossRef

83.

Lahaye C, Soubrier M, Mulliez A, Bardin T, Cantagrel A, Combe B, et al. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registry. Rheumatology (Oxford). 2016;. doi:10.1093/rheumatology/kev437.

84.

Pers YM, Schaub R, Constant E, Lambert J, Godfrin-Valnet M, Fortunet C, et al. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine. 2015;82(1):25–30. doi:10.1016/j.jbspin.2014.07.010.PubMedCrossRef

85.

Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580–4. doi:10.1136/ard.2008.092866.PubMedPubMedCentralCrossRef

86.

Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken). 2015;67(5):731–6. doi:10.1002/acr.22470.PubMedCrossRef

87.

Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, Dallinga-Thie GM, Levels JH, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013;229(1):174–81. doi:10.1016/j.atherosclerosis.2013.04.031.PubMedCrossRef

88.

Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol. 2015;67(2):372–80. doi:10.1002/art.38920.PubMedCrossRef

89.

Payet S, Soubrier M, Perrodeau E, Bardin T, Cantagrel A, Combe B, et al. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry. Arthritis Care Res (Hoboken). 2014;66(9):1289–95.PubMedCrossRef

90.

Wendler J, Burmester GR, Sorensen H, Krause A, Richter C, Tony HP, et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res Ther. 2014;16(2):R80. doi:10.1186/ar4521.PubMedPubMedCentralCrossRef

91.

van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761–6. doi:10.3899/jrheum.150051.PubMedCrossRef

92.

Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016–26. doi:10.1002/acr.22246.PubMedCrossRef

93.

Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, et al. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks. J Rheumatol. 2015;42(5):786–93. doi:10.3899/jrheum.141288.PubMedCrossRef

94.

Nusslein HG, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskel Disord. 2014;15:14. doi:10.1186/1471-2474-15-14.CrossRef

95.

Tanaka Y, Kubo S, Yamanaka H, Amano K, Hirata S, Tanaka E, et al. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia((R)) as Biological Intensive Treatment for RA (ORBIT) study. Modern Rheumatol Japan Rheum Assoc. 2014;24(5):754–62. doi:10.3109/14397595.2013.872862.CrossRef

96.

Du Pan SM, Scherer A, Gabay C, Finckh A. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis. 2012;71(6):997–9. doi:10.1136/annrheumdis-2011-200882.PubMedCrossRef

97.

Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann Rheum Dis. 2012;71(11):1815–9. doi:10.1136/annrheumdis-2011-201109.PubMedCrossRef

98.

Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009;36(4):736–42. doi:10.3899/jrheum.080813.PubMedCrossRef

99.

Simon TA, Smitten AL, Franklin J, Askling J, Lacaille D, Wolfe F, et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis. 2009;68(12):1819–26. doi:10.1136/ard.2008.097527.PubMedPubMedCentralCrossRef

100.

Salmon JH, Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis. 2015;. doi:10.1136/annrheumdis-2015-207362.PubMedCentral

101.

Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65(3):476–80. doi:10.1002/acr.21838.PubMedCrossRef

102.

Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. Arthritis Res Ther. 2015;17:357. doi:10.1186/s13075-015-0863-3.PubMedPubMedCentralCrossRef

103.

Crnkic Kapetanovic M, Saxne T, Jonsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R171. doi:10.1186/ar4358.PubMedPubMedCentralCrossRef

Titel: Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance
verfasst von: Alla Ishchenko
Rik J. Lories
Publikationsdatum: 06.05.2016
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 6/2016
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-016-0374-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Associations Between Statin Use and Physical Function in Older Adults from The Netherlands and Australia: Longitudinal Aging Study Amsterdam and Australian Longitudinal Study on Women’s Health

A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras

The FORTA (Fit fOR The Aged) List 2015: Update of a Validated Clinical Tool for Improved Pharmacotherapy in the Elderly

Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia

Impact of Drug–Drug and Drug–Disease Interactions on Gait Speed in Community-Dwelling Older Adults

Pharmacological Management of Elderly Patients with Asthma–Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin